XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals

Stock News04-14

XUANZHUBIO-B (02575) saw its shares rise more than 12% in afternoon trading. At the time of writing, the stock was up 4.97%, trading at HK$32.54 with a turnover of HK$80.7147 million. The company announced it has received a formal filing notice from the China Securities Regulatory Commission, completing the conversion of 357 million non-tradable shares held by six shareholders into 357 million H-shares. Upon completion, XUANZHUBIO-B's tradable share base is expected to expand significantly, leading to a fundamental improvement in liquidity. Notably, on April 9, XUANZHUBIO-B announced it had entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, the company granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa. XUANZHUBIO-B is expected to receive an upfront payment and cumulative milestone payments exceeding $100 million, in addition to royalties based on sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1142636519?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142636519","market":"hk","top_or_hot":-1,"title":"XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals","media":"Stock News","content":"<p>XUANZHUBIO-B (02575) saw its shares rise more than 12% in afternoon trading. At the time of writing, the stock was up 4.97%, trading at HK$32.54 with a turnover of HK$80.7147 million. The company announced it has received a formal filing notice from the China Securities Regulatory Commission, completing the conversion of 357 million non-tradable shares held by six shareholders into 357 million H-shares. Upon completion, XUANZHUBIO-B's tradable share base is expected to expand significantly, leading to a fundamental improvement in liquidity. Notably, on April 9, XUANZHUBIO-B announced it had entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, the company granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa. XUANZHUBIO-B is expected to receive an upfront payment and cumulative milestone payments exceeding $100 million, in addition to royalties based on sales.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXUANZHUBIO-B Shares Surge Over 12% in Afternoon Trading Following H-Share Reform Approval and Drug Licensing Deals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-14 14:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XUANZHUBIO-B (02575) saw its shares rise more than 12% in afternoon trading. At the time of writing, the stock was up 4.97%, trading at HK$32.54 with a turnover of HK$80.7147 million. The company announced it has received a formal filing notice from the China Securities Regulatory Commission, completing the conversion of 357 million non-tradable shares held by six shareholders into 357 million H-shares. Upon completion, XUANZHUBIO-B's tradable share base is expected to expand significantly, leading to a fundamental improvement in liquidity. Notably, on April 9, XUANZHUBIO-B announced it had entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, the company granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa. XUANZHUBIO-B is expected to receive an upfront payment and cumulative milestone payments exceeding $100 million, in addition to royalties based on sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1142636519","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142636519","pubTimestamp":1776147021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"XUANZHUBIO-B (02575) saw its shares rise more than 12% in afternoon trading. At the time of writing, the stock was up 4.97%, trading at HK$32.54 with a turnover of HK$80.7147 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1191":"制药","02575":"轩竹生物-B","BK4585":"ETF&股票定投概念"},"translate_title":"继H股改革批准和药品许可交易后，轩竹生物-B股在下午交易中飙升超过12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02575":1},"content_text":"XUANZHUBIO-B (02575) saw its shares rise more than 12% in afternoon trading. At the time of writing, the stock was up 4.97%, trading at HK$32.54 with a turnover of HK$80.7147 million. The company announced it has received a formal filing notice from the China Securities Regulatory Commission, completing the conversion of 357 million non-tradable shares held by six shareholders into 357 million H-shares. Upon completion, XUANZHUBIO-B's tradable share base is expected to expand significantly, leading to a fundamental improvement in liquidity. Notably, on April 9, XUANZHUBIO-B announced it had entered into a licensing and supply agreement with Boston Oncology for two of its self-developed oncology drugs, piroplinib (Xuan Yue Ning®) and diroac (Xuan Fei Ning®). Under the agreement, the company granted exclusive commercialization rights in 21 countries and regions across the Middle East and North Africa. XUANZHUBIO-B is expected to receive an upfront payment and cumulative milestone payments exceeding $100 million, in addition to royalties based on sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1142636519","isCrawlerRequest":true}